Comprehensive Evaluation of Lipid Nanoparticles and Polyplex Nanomicelles for Muscle-Targeted mRNA Delivery

Area of Science:

• Biotechnology
• Nanomedicine
• Drug Delivery

Background:

• Messenger RNA (mRNA) therapeutics are increasingly important for treating cancer, infectious diseases, and genetic disorders.
• Lipid nanoparticles (LNPs) are promising for mRNA delivery but face challenges with toxicity and immunogenicity.
• Efficient and safe delivery systems are crucial for advancing mRNA-based therapies.

Purpose of the Study:

• To compare the performance of novel polyplex nanomicelles against established lipid nanoparticles (LNPs) for mRNA delivery.
• To evaluate key parameters including delivery efficiency, organ toxicity, muscle damage, immune response, and pain.
• To determine the suitability of each carrier for specific therapeutic applications.

Main Methods:

• Development and characterization of a cationic polymer-based nanomicelle carrier (PEG-PAsp(DET)).
• Comparative analysis of nanomicelles and LNPs (SM-102) in preclinical models.
• Assessment of protein expression kinetics, inflammatory markers, tissue damage, and immune responses.

Main Results:

• Nanomicelles demonstrated sustained protein production and lower inflammation, indicating therapeutic potential.
• Lipid nanoparticles showed rapid mRNA expression and a strong immune response, suitable for vaccines.
• Distinct characteristics were observed between nanomicelles and LNPs regarding safety and efficacy profiles.

Conclusions:

• Polyplex nanomicelles and LNPs possess different strengths for mRNA delivery applications.
• Nanomicelles are promising for therapeutic applications requiring sustained effects and reduced inflammation.
• LNPs are advantageous for vaccine development due to their ability to elicit rapid and potent immune responses.
• These findings support the tailored optimization of mRNA delivery systems for specific medical needs.